Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single IV Doses of BV100 in Healthy Males
NCT04636983Phase 1Completed
- Sponsor
- BioVersys AG
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Acinetobacter baumannii infection comparing BV100 with Placebo (2 arms). Primary endpoint: Nature, occurrence, and severity of treatment-emergent adverse events at 10 Days. Started Nov 2020; status: completed.
02
Drugs
BV100
03
Conditions
Acinetobacter baumannii infection
Beyond the preview
Go deeper on NCT04636983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04636983.